Axsome Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $49.3M | $14.7M | $84.7M |
| Jun 2022 | $93.5M | $15.2M | $73.4M |
| Sep 2022 | $93.9M | $157.4M | $227.5M |
| Dec 2022 | $94.3M | $109.6M | $200.8M |
| Mar 2023 | $147.6M | $111.8M | $246.5M |
| Jun 2023 | $176.8M | $278.8M | $437.1M |
| Sep 2023 | $177.4M | $269.5M | $416.6M |
| Dec 2023 | $178.1M | $191.0M | $386.2M |
| Mar 2024 | $178.7M | $144.0M | $331.4M |
| Jun 2024 | $179.3M | $102.9M | $315.7M |
| Sep 2024 | $180.0M | $92.9M | $327.3M |
| Dec 2024 | $180.7M | $57.0M | $315.4M |
| Mar 2025 | $181.4M | $53.2M | $300.9M |
| Jun 2025 | $117.5M | $73.1M | $303.0M |
| Sep 2025 | $117.6M | $73.7M | $325.3M |
| Dec 2025 | $117.7M | $88.3M | $322.9M |
| Mar 2026 | $117.9M | $54.6M | $305.1M |
| Jun 2026 | $118.0M | $83.3M | $319.9M |